1. Home
  2. BHFAP vs SCLXW Comparison

BHFAP vs SCLXW Comparison

Compare BHFAP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brighthouse Financial Inc.

BHFAP

Brighthouse Financial Inc.

HOLD

Current Price

$16.11

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.18

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHFAP
SCLXW
Founded
N/A
N/A
Country
United States
United States
Employees
1400
30
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BHFAP
SCLXW
Price
$16.11
$0.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
4.0K
Earning Date
N/A
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
N/A
$0.18
52 Week High
N/A
$0.18

Technical Indicators

Market Signals
Indicator
BHFAP
SCLXW
Relative Strength Index (RSI) 62.90 55.73
Support Level $15.60 $0.07
Resistance Level $16.14 $0.18
Average True Range (ATR) 0.37 0.03
MACD 0.11 0.01
Stochastic Oscillator 73.37 91.84

Price Performance

Historical Comparison
BHFAP
SCLXW

About BHFAP Brighthouse Financial Inc.

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: